ProCE Banner Series

Evolving Therapeutic Options in Aggressive B-Cell Lymphomas: Expert Guidance for the Community Multidisciplinary Team

Register now for this interactive, case-based workshop series to effectively personalize the care of patients with aggressive B-cell lymphomas, learn how to use predictive and prognostic markers to guide treatment selection, and hear about the recent and evolving treatment strategies for the optimal management of patients with these aggressive B-cell lymphomas. After the workshop, view the on-demand webcast and download the associated slideset for use in your clinic.

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for medical oncologists, nurses, pharmacists, hematologists, and other healthcare professionals who treat patients with aggressive B cell lymphomas.

All Events

Evolving Therapeutic Options in Aggressive B-Cell Lymphomas: Expert Guidance for the Community Multidisciplinary Team [Open Registration]

Upcoming Events

February

22

2024

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group DC, Washington, District of Columbia

Past Events

February

19

2024

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MD, Baltimore, Maryland

Faculty

ProCE Banner Faculty
Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

ProCE Banner Faculty
John Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Topics

  • Introduction
  • Overview of Aggressive B-Cell Lymphomas: LBCL, DLBCL, MCL
  • Case Discussions: Key Considerations for the Multidisciplinary Team
    • Selection and Sequencing of New and Emerging Agents
    • Differentiating Among Classes of Agents and Among Agents Within Each Class
    • Integrating Precision Medicine Approaches Into the Treatment Algorithm
    • Supportive Measures to Partner With Patients in Their Care
  • Investigational Agents: Ongoing Clinical Trials
  • Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of healthcare professionals to individualize the therapeutic management of patients with LBCL, DLBCL, and MCL. 

Target Audience
This educational program is intended for medical oncologists, nurses, pharmacists, hematologists, and other healthcare professionals who treat patients with aggressive B cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement expert-recommended predictive and prognostic molecular profiling for appropriate patients with aggressive B-cell lymphoma subtypes to help guide treatment decisions
  • Select therapeutic regimens for patients with LBCL, DLBCL, or MCL based on available clinical data, line of treatment, disease characteristics, and patient goals and preferences to optimize clinical outcomes
  • Identify patients with aggressive B-cell lymphomas who are eligible for and likely to benefit from enrollment in a clinical trial
  • Integrate optimal supportive care strategies to manage adverse events associated with novel treatment regimens for aggressive B-cell lymphoma

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-026-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Incyte Corporation.